Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 23

Sort by

Sort Order Select

Journal Articles

T-Cell Monitoring for the Recently Expanded Repertoire of HLA Class I-Restricted Minor Histocompatibility Antigens Using Barcoded Peptide-MHC Multimers

Kyra J. Fuchs, Marcus Göransson, Michel G.D. Kester, Natasja W. Ettienne, Marian van de Meent, Rob C.M. de Jong, Eva A.S. Koster, Constantijn J.M. Halkes, Ferenc A. Scheeren, Mirjam H.M. Heemskerk, Peter Van Balen, J.H. Frederik Falkenburg, Sine R. Hadrup, Marieke Griffioen

Blood (2024) 144 (Supplement 1): 691.

https://doi.org/10.1182/blood-2024-197955

Published: 2024

Journal Articles

T Cell Receptor-Based Targeting of Immunoglobulin Constant Domains for Treatment of Multiple Myeloma

Miranda H. Meeuwsen, Anne K. Wouters, Tassilo L.A. Wachsmann, Renate S. Hagedoorn, Dennis F.G. Remst, Michel G.D. Kester, Dirk M. van der Steen, Arnoud H. de Ru, Peter A. van Veelen, J.H. Frederik Falkenburg, Mirjam H.M. Heemskerk

Blood (2022) 140 (Supplement 1): 10292–10293.

https://doi.org/10.1182/blood-2022-170314

Published: 2022

Journal Articles

Broadly Applicable TCR Based Therapy for Multiple Myeloma Targeting the Jchain

Miranda H. Meeuwsen, Anne K. Wouters, Tassilo L.A. Wachsmann, Renate S. Hagedoorn, Michel G.D. Kester, Dennis F.G. Remst, Dirk M. van der Steen, Arnoud H. de Ru, Els P. van Hees, Marieke Griffioen, Peter A. van Veelen, J.H. Frederik Falkenburg, Mirjam H.M. Heemskerk

Blood (2022) 140 (Supplement 1): 4498–4499.

https://doi.org/10.1182/blood-2022-156923

Published: 2022

Journal Articles

Sars-Cov-2-Specific CD4 + and CD8 + T Cell Responses Can Originate from Cross-Reactive CMV-Specific T Cells

Cilia R. Pothast, Romy C. Dijkland, Melissa Thaler, Renate S. Hagedoorn, Michel G.D. Kester, Anne K. Wouters, Pieter S. Hiemstra, Martijn J. van Hemert, Stephanie Gras, J.H. Frederik Falkenburg, Mirjam H.M. Heemskerk

Blood (2022) 140 (Supplement 1): 2631–2632.

https://doi.org/10.1182/blood-2022-156715

Published: 2022

Journal Articles

Immunotherapy By Targeting CD45 in Mismatched HLA-DP to Treat Patients after Allogeneic Stem Cell Transplantation

Nadine E. Struckman, Sebastian Klobuch, Michel G.D. Kester, Wendy de Klerk, Arnoud H. de Ru, Mirjam H.M. Heemskerk, Peter A. van Veelen, Peter van Balen, J.H.Frederik Falkenburg, Marieke Griffioen

Blood (2022) 140 (Supplement 1): 4545–4546.

https://doi.org/10.1182/blood-2022-166282

Published: 2022

Journal Articles

HLA-DM Mediates Permissiveness of HLA-DPB1 T Cell Epitope Mismatches in Unrelated HCT

Maximilian Metzing, Pietro Crivello, Thuja Meurer, Michel G.D. Kester, ing., Dominik Megger, Weiqiang Chen, Peter Van Balen, MD, Marieke Griffioen, PhD, Peter A. Horn, Barbara Sitek, J.H.Frederik Falkenburg, MD PhD, Esteban Arrieta-Bolaños, Katharina Fleischhauer, MD

Blood (2019) 134 (Supplement_1): 3211.

https://doi.org/10.1182/blood-2019-129921

Published: 2019

Journal Articles

Mutated NPM1 As Target for Immunotherapy of Acute Myeloid Leukemia

Dyantha I. Van Der Lee, BSc., Helena M. Bijen, MSc, Renate S. Hagedoorn, ing., Willy M. Honders, ing., Michel G.D. Kester, ing., Dirk M. van der Steen, ing., Arnoud H. de Ru, ing., Inge Jedema, PhD, Hendrik Veelken, MD PhD, Mirjam H.M. Heemskerk, PhD, Peter A. van Veelen, PhD, J.H. Frederik Falkenburg, MD PhD, Marieke Griffioen, PhD

Blood (2017) 130 (Supplement 1): 168.

https://doi.org/10.1182/blood.V130.Suppl_1.168.168

Published: 2017

Journal Articles

Endogenous Immunoglobulin-Derived Neoepitopes Are Processed and Form a Sizeable Fraction of the HLA Class I Ligandome of Human Lymphoma Cells

Cornelis A.M. van Bergen, PhD, Dirk M. van der Steen, Michel G.D. Kester, Marvyn T. Koning, BSc, Peter A. van Veelen, PhD, Marieke Griffioen, PhD, J.H. Frederik Falkenburg, MD PhD, Mirjam H.M. Heemskerk, PhD, Hendrik Veelken, MD PhD, Marcelo A Navarrete, MD PhD

Blood (2016) 128 (22): 914.

https://doi.org/10.1182/blood.V128.22.914.914

Published: 2016

Journal Articles

T Cell Receptor Gene Therapy Targeting the Intracellular Transcription Factor Bob1 for the Treatment of Multiple Myeloma and Other B Cell Malignancies

Lorenz Jahn, Renate S. Hagedoorn, Pleun Hombrink, PhD, Michel G.D. Kester, Dirk M. van der Steen, Chopie Hassan, Marjolein P. Schoonakker, Erwin van der Pijl, Peter A. van Veelen, PhD, J.H. Frederik Falkenburg, MD PhD, Mirjam H.M. Heemskerk, PhD

Blood (2015) 126 (23): 3002.

https://doi.org/10.1182/blood.V126.23.3002.3002

Published: 2015

Journal Articles

T Cell Receptors Specific for the Intracellular Transcription Factor Bob1 Allow Efficient Targeting of Human B Cell Leukemia and Multiple Myeloma

Lorenz Jahn, Pleun Hombrink, Michel G.D. Kester, Dirk M. van der Steen, Renate S. Hagedoorn, Chopie Hassan, Marjolein P. Schoonakker, Erwin van der Pijl, Peter A. van Veelen, PhD, J.H. Frederik Falkenburg, MD PhD, Mirjam H.M. Heemskerk, PhD

Blood (2014) 124 (21): 3832.

https://doi.org/10.1182/blood.V124.21.3832.3832

Published: 2014

Journal Articles

High-Affinity CD20-Specific T-Cell Receptors Suitable for Adoptive Immunotherapy in the Treatment of CD20 low B-Cell Malignancies

Lorenz Jahn, Pleun Hombrink, Chopie Hassan, Michel G.D. Kester, Renate S. Hagedoorn, Dirk M. van der Steen, Marjolein P. Schoonakker, J.H. Frederik Falkenburg, MD PhD, Peter A. van Veelen, PhD, Mirjam H.M. Heemskerk, PhD

Blood (2014) 124 (21): 3837.

https://doi.org/10.1182/blood.V124.21.3837.3837

Published: 2014

Journal Articles

Imprint Of Early CMV Reactivation On The Reconstituting T-Lymphocyte Compartment One and Two Year After Hematopoietic Stem Cell Transplantation

Gertjan Lugthart, MD, Monique M. van Ostaijen-Ten Dam, Cornelia M. Jol-van der Zijde, Tessa C. van Holten, Michel G.D. Kester, Mirjam H.M. Heemskerk, PhD, Robbert G.M. Bredius, MD, PhD, Maarten J.D. van Tol, PhD, Arjan C. Lankester, MD, PhD

Blood (2013) 122 (21): 3295.

https://doi.org/10.1182/blood.V122.21.3295.3295

Published: 2013

Journal Articles

LB-ARHGDIB-1R As Novel Minor Histocompatibility Antigen For Therapeutic Application

Margot J Pont, Willemijn Hobo, PhD, M. Willy Honders, Simone A.P. van Luxemburg-Heijs, Michel G.D. Kester, Cornelis A.M. van Bergen, Harry Dolstra, PhD, J.H. Frederik Falkenburg, MD, PhD, Marieke Griffioen, PhD

Blood (2013) 122 (21): 4465.

https://doi.org/10.1182/blood.V122.21.4465.4465

Published: 2013

Journal Articles

HLA-Peptidomics and the Identification of Clinical Relevant Minor Histocompatibility Antigens,

Pleun Hombrink, MSc, Chopie Hassan, Michel G.D. Kester, Cornelis A.M. van Bergen, J.H.F. Falkenburg, MD, PhD, Peter A. van Veelen, Mirjam H.M. Heemskerk, PhD

Blood (2011) 118 (21): 4038.

https://doi.org/10.1182/blood.V118.21.4038.4038

Published: 2011

Journal Articles

Association of Disparities in Known Minor Histocompatibility Antigens with Relapse-Free Survival and Graft-Versus-Host-Disease Upon Allogeneic Stem Cell Transplantation,

Willemijn Hobo, Kelly Broen, Walter J.F.M. van der Velden, MD, PhD, Annelies Greupink-Draaisma, Niken Adisty, Yannick Wouters, Michel G.D. Kester, Hanny Fredrix, Joop H. Jansen, PhD, Bert A. van der Reijden, PhD, J.H. Frederik Falkenburg, Theo de Witte, MD, PhD, Frank W.M.B. Preijers, PhD, Anton Schattenberg, MD, PhD, Ton Feuth, Nicole N.A. Blijlevens, MD, PhD, Nicolaas Schaap, MD, PhD, Harry Dolstra, PhD

Blood (2011) 118 (21): 4136.

https://doi.org/10.1182/blood.V118.21.4136.4136

Published: 2011

Journal Articles

Allogeneic HLA-A2-Restricted WT1-Specific T Cells From Mismatched Donors Are Highly Reactive but Show Potentially Hazardous Promiscuity.

Willem J.J. Falkenburg, J. Joseph Melenhorst, PhD, Michel G.D. Kester, Pleun Hombrink, Mirjam H.M. Heemskerk, PhD, Emma Gostick, David A. Price, J.H. Frederik Falkenburg, MD, PhD, A.John Barrett, MD, PhD, Inge Jedema, PhD

Blood (2009) 114 (22): 4081.

https://doi.org/10.1182/blood.V114.22.4081.4081

Published: 2009

Journal Articles

High Avidity HLA-A2-Restricted CD8+ T Cells against the Wilms Tumor Protein (WT1) Can Be Isolated Only from HLA-A2 Negative Donors Not Subjected to HLA-A2-Mediated Thymic Deletion

Inge Jedema, PhD, Marian van de Meent, Willem J.J. Falkenburg, Michel G.D. Kester, Roel Willemze, J.H. Frederik Falkenburg

Blood (2008) 112 (11): 3895.

https://doi.org/10.1182/blood.V112.11.3895.3895

Published: 2008

Journal Articles

Sequence Dependent Efficiency of Cross-Presentation in MHC Class I Requires Rational Design of Long Synthetic Peptides for Vaccination or Ex Vivo Activation

Maarten L. Zandvliet, J.H. Frederik Falkenburg, Michel G.D. Kester, Arnoud H. de Ru, Peter A. van Veelen, Roelof Willemze, Henk-Jan Guchelaar, Pauline Meij

Blood (2008) 112 (11): 3904.

https://doi.org/10.1182/blood.V112.11.3904.3904

Published: 2008

Journal Articles

GVHD in HLA-A2 Mismatched Transplantation Caused by a Combined CD8 Response Directed Against HLA-A2 and a CD4 Response Recognizing an HLA-A2 Derived Peptide in HLA-DR1.

Avital Amir, Menno A.W.G. van der Hoorn, Erik W.A. Marijt, Michel G.D. Kester, Roelof Willemze, J.H. Frederik Falkenburg, Mirjam H.M. Heemskerk

Blood (2006) 108 (11): 5164.

https://doi.org/10.1182/blood.V108.11.5164.5164

Published: 2006

Journal Articles

Identification of the Angiogenic Endothelial Cell Growth Factor-1/Thymidine Phosphorylase as a Target for Immunotherapy of Cancer.

Elisabeth H. Slager, PhD, M. Willy Honders, Edith D. van der Meijden, Simone A.P. van Luxemburg-Heijs, Freke M. Kloosterboer, PhD, Michel G.D. Kester, Inge Jedema, PhD, W.A. Erik Marijt, PhD, MD, M. Ronald Schaafsma, PhD, MD, J.H. Frederik Falkenburg, PhD, MD, Roel Willemze, PhD, MD

Blood (2005) 106 (11): 3094.

https://doi.org/10.1182/blood.V106.11.3094.3094

Published: 2005

NARROW

T-Cell Monitoring for the Recently Expanded Repertoire of HLA Class I-Restricted Minor Histocompatibility Antigens Using Barcoded Peptide-MHC Multimers

T Cell Receptor-Based Targeting of Immunoglobulin Constant Domains for Treatment of Multiple Myeloma

Broadly Applicable TCR Based Therapy for Multiple Myeloma Targeting the Jchain

Sars-Cov-2-Specific CD4 + and CD8 + T Cell Responses Can Originate from Cross-Reactive CMV-Specific T Cells

Immunotherapy By Targeting CD45 in Mismatched HLA-DP to Treat Patients after Allogeneic Stem Cell Transplantation

HLA-DM Mediates Permissiveness of HLA-DPB1 T Cell Epitope Mismatches in Unrelated HCT

Mutated NPM1 As Target for Immunotherapy of Acute Myeloid Leukemia

Endogenous Immunoglobulin-Derived Neoepitopes Are Processed and Form a Sizeable Fraction of the HLA Class I Ligandome of Human Lymphoma Cells

T Cell Receptor Gene Therapy Targeting the Intracellular Transcription Factor Bob1 for the Treatment of Multiple Myeloma and Other B Cell Malignancies

T Cell Receptors Specific for the Intracellular Transcription Factor Bob1 Allow Efficient Targeting of Human B Cell Leukemia and Multiple Myeloma

High-Affinity CD20-Specific T-Cell Receptors Suitable for Adoptive Immunotherapy in the Treatment of CD20 low B-Cell Malignancies

Imprint Of Early CMV Reactivation On The Reconstituting T-Lymphocyte Compartment One and Two Year After Hematopoietic Stem Cell Transplantation

LB-ARHGDIB-1R As Novel Minor Histocompatibility Antigen For Therapeutic Application

HLA-Peptidomics and the Identification of Clinical Relevant Minor Histocompatibility Antigens,

Association of Disparities in Known Minor Histocompatibility Antigens with Relapse-Free Survival and Graft-Versus-Host-Disease Upon Allogeneic Stem Cell Transplantation,

Allogeneic HLA-A2-Restricted WT1-Specific T Cells From Mismatched Donors Are Highly Reactive but Show Potentially Hazardous Promiscuity.

High Avidity HLA-A2-Restricted CD8+ T Cells against the Wilms Tumor Protein (WT1) Can Be Isolated Only from HLA-A2 Negative Donors Not Subjected to HLA-A2-Mediated Thymic Deletion

Sequence Dependent Efficiency of Cross-Presentation in MHC Class I Requires Rational Design of Long Synthetic Peptides for Vaccination or Ex Vivo Activation

GVHD in HLA-A2 Mismatched Transplantation Caused by a Combined CD8 Response Directed Against HLA-A2 and a CD4 Response Recognizing an HLA-A2 Derived Peptide in HLA-DR1.

Identification of the Angiogenic Endothelial Cell Growth Factor-1/Thymidine Phosphorylase as a Target for Immunotherapy of Cancer.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only